1-8 of 8
Joshi J. Alumkal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead, III, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia, Eric Campeau, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4923–4936.
https://doi.org/10.1158/1078-0432.CCR-20-4968
Published: 01 September 2021
View article titled, BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Open the PDF for BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program in another window
Includes: Supplementary data
Journal Articles

Autoantibody Landscape in Patients with Advanced Prostate Cancer

William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga Carretero, Ivan Perez Garcilazo, Meng Zhang, Shuang G. Zhao, Martin Sjöström, David A. Quigley, Jonathan Chou, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Primo Lara, Kim N. Chi, Robert E. Reiter, Joshi J. Alumkal, Alan Ashworth, Rahul Aggarwal, Eric J. Small, Patrick S. Daugherty, Antoni Ribas, David Y. Oh, John C. Shon, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6204–6214.
https://doi.org/10.1158/1078-0432.CCR-20-1966
Published: 01 December 2020
View article titled, Autoantibody Landscape in Patients with Advanced Prostate Cancer
Open the PDF for Autoantibody Landscape in Patients with Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Rahul R. Aggarwal, Michael T. Schweizer, David M. Nanus, Allan J. Pantuck, Elisabeth I. Heath, Eric Campeau, Sarah Attwell, Karen Norek, Margo Snyder, Lisa Bauman, Sanjay Lakhotia, Felix Y. Feng, Eric J. Small, Wassim Abida, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5338–5347.
https://doi.org/10.1158/1078-0432.CCR-20-1707
Published: 15 October 2020
View article titled, A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Open the PDF for A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

Xiangnan Guan, Duanchen Sun, Eric Lu, Joshua A. Urrutia, Robert Evan Reiter, Matthew Rettig, Christopher P. Evans, Primo Lara, Jr, Martin Gleave, Tomasz M. Beer, George V. Thomas, Jiaoti Huang, Rahul R. Aggarwal, David A. Quigley, Adam Foye, William S. Chen, Jack Youngren, Alana S. Weinstein, Joshua M. Stuart, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4616–4624.
https://doi.org/10.1158/1078-0432.CCR-19-2303
Published: 01 September 2020
View article titled, Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary-Ellen Taplin, James Babb, Ethan S. Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk Moore, Robert DiPaola, Tomasz M. Beer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2672.
https://doi.org/10.1158/1078-0432.CCR-19-0442
Published: 15 April 2019
View article titled, Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Open the PDF for Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer in another window
Journal Articles

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary-Ellen Taplin, James Babb, Ethan S. Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk Moore, Robert DiPaola, Tomasz M. Beer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 52–63.
https://doi.org/10.1158/1078-0432.CCR-18-1589
Published: 03 January 2019
View article titled, Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Open the PDF for Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald F. Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J. de Boer, Margaret K. Yu, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3544–3551.
https://doi.org/10.1158/1078-0432.CCR-16-2509
Published: 13 July 2017
View article titled, Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Open the PDF for Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen

Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin, Daniel J. George, for the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4218–4227.
https://doi.org/10.1158/1078-0432.CCR-14-0356
Published: 13 August 2014
View article titled, Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Open the PDF for Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen in another window
Includes: Supplementary data